Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports.

ATRA has been the topic of a number of other reports. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 4th. ValuEngine raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Mizuho reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, April 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Three equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $49.00.

Shares of NASDAQ ATRA opened at $31.86 on Thursday. Atara Biotherapeutics has a one year low of $27.85 and a one year high of $54.45. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -6.05 and a beta of 2.25.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.44). Equities research analysts predict that Atara Biotherapeutics will post -5.99 earnings per share for the current year.

In other news, CEO Isaac E. Ciechanover sold 3,900 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $37.04, for a total transaction of $144,456.00. Following the sale, the chief executive officer now directly owns 332,243 shares of the company’s stock, valued at approximately $12,306,280.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Christopher Haqq sold 12,375 shares of the stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $38.62, for a total value of $477,922.50. Following the sale, the executive vice president now directly owns 282,903 shares in the company, valued at $10,925,713.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 162,524 shares of company stock worth $6,069,971. 10.60% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its position in shares of Atara Biotherapeutics by 79.7% during the fourth quarter. Deutsche Bank AG now owns 221,084 shares of the biotechnology company’s stock valued at $7,678,000 after buying an additional 98,042 shares during the last quarter. Geode Capital Management LLC raised its position in Atara Biotherapeutics by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 498,078 shares of the biotechnology company’s stock valued at $17,303,000 after purchasing an additional 46,546 shares during the last quarter. Norges Bank bought a new position in Atara Biotherapeutics during the 4th quarter valued at approximately $20,648,000. Dimensional Fund Advisors LP raised its position in Atara Biotherapeutics by 107.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock valued at $16,500,000 after purchasing an additional 245,832 shares during the last quarter. Finally, FMR LLC raised its position in Atara Biotherapeutics by 1.8% during the 4th quarter. FMR LLC now owns 5,274,169 shares of the biotechnology company’s stock valued at $183,225,000 after purchasing an additional 93,432 shares during the last quarter.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading: What is a Tariff?

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.